Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, is a drug that is frequently included in highly active antiretroviral therapy for treatment of HIV infection. Decreased bioavailability and increased toxicity limit its use. We report a formulation of efavirenz-loaded lactoferrin nanoparticles (lacto-EFV-nano) for oral delivery which exhibited significantly improved pharmacological properties coupled with reduced toxicity compared with its free form.
Introduction
According to the current epidemiological data sheet, approximately 35 million of the world's population are living with HIV/AIDS [1] . Progression to AIDS is determined primarily on the basis of a low CD4 count, which may eventually lead to immunological failure [2, 3] . The Food and Drug Administration (FDA), USA has approved six classes of drugs for treatment of HIV infection: (1) non-nucleoside reverse transcriptase inhibitors (NNRTIs), (2) nucleoside reverse transcriptase inhibitors (NRTIs), (3) integrase inhibitors, (4) protease inhibitors (PIs), (5) fusion inhibitors and (6) co-receptor antagonists [4] . Treatment of AIDS started with mono-drug therapy in the late 1990s, subsequently shifted to combination therapy with two drugs, and is currently triple-drug combination therapy. Triple-drug combination highly active antiretroviral therapy (HAART) includes two NRTIs plus one NNRTI [4] [5] [6] . Efavirenz (EFV) is highly lipophilic with a partition coefficient (LogP) of 5.4 [7] , having very poor aqueous solubility (8.3 lg/mL) [8] . It is a very commonly prescribed combination drug in first-line antiretroviral regimens for AIDS treatment [9] . EFV exhibits very high plasma protein binding (> 99%) [10] , which results in very low bioavailability of 40-45%, which in turn necessitates administration of very high doses [11] . The pharmacological activity of a drug is mainly dependent on the unbound fraction of the drug in the blood plasma. Various attempts have been made to improve the pharmacokinetic (PK) profiles of drugs characterized by poor bioavailability, including the introduction of nanotechnology-based delivery systems using nanoparticles (NPs) and nanosuspensions [11] [12] [13] . Among these, the NP-based system is one of the most promising drug delivery systems [14] . To deliver the drug in a controlled and sustained manner at the site of action and to maintain the desired therapeutic concentration over a long period, various biodegradable polymers have been used as nanocarriers. Our study was concerned with the development of a lactoferrin (Lf)-based nanodelivery system. Lf is an iron-binding protein present in external secretions such as tears, nasal fluid, saliva, pancreatic and gastrointestinal secretions, urine and reproductive tissue secretions [15] [16] [17] . It is a biodegradable multifunctional protein having various properties such as anti-inflammatory, virucidal and antimicrobial properties. These properties make it a more efficient and safer drug delivery system compared with systems based on other molecules [16] . In addition to these qualities, it is easily available at low cost and is thus an ideal material for use in the development of NPs. The aim of the present study was to develop a highly stable Lf-based oral nanoformulation for delivery of EFV with sustained optimum release of the drug along with reduced toxicity and improved pharmacological properties and anti-HIV activity.
Methods

Nanoparticle preparation
Nanoparticles (NPs) were prepared by the Sol-oil method [18] using a fixed concentration of EFV and varying concentrations of Lf (Supporting Information Table S1 ).
Initially, in each of a set of five tubes, 10 mg of EFV was dissolved in 100 lL of methanol. In another set of five separate tubes, an increasing concentration of Lf (10, 20, 30 , 40 and 50 mg) was dissolved in 500 lL of phosphate-buffered saline (PBS; pH 7.4). EFV and Lf were mixed in the ratio shown in Table S1 and incubated on ice for 60 min. The resultant mixture was slowly added to 30 mL of olive oil at 4°C with continuous dispersion by gentle manual vortexing. The sample was sonicated for 15 min at 4°C using the narrow stepped titanium probe of an ultrasonic homogenizer. The sonication amplitude was 5 lm and the pulses were 30-S long, with an interval of 1 min between successive pulses. The resulting mixture was immediately frozen in liquid nitrogen for 15 min and was then thawed on ice for 4 h. The particles formed were pelleted down by centrifugation at 2915 9 g for 10 min. The supernatant was then discarded and the pellet was thoroughly washed with diethyl ether and dispersed in PBS (pH 7.4). NPs loaded with EFV are referred to as "lacto-EFV-nano" and those without EFV as "blank-NPs" or "lacto-nano".
Nanoparticle characterization
Size measurement of nanoparticles The diameter of NPs was measured using field emission scanning electron microscopy (FE-SEM; Philips FEI-XL 30 ESEM; FEI, Hillsboro, OR). The sample for FE-SEM was prepared as follows. Freshly prepared NPs were suspended in 1 mL of Milli-Q (Merck-Millipore corporation, Darmstadt, Germany). A drop of suspended NPs was dripped onto a clean sterile glass slide and dried overnight. Particles were coated with gold and were observed under the microscope.
Measurement of the size distribution, polydispersity index (PDI) and zeta potential The size distribution and PDI of blank-NPs and lacto-EFV-nano in suspension form were measured with dynamic light scattering (DLS) methods using the NP analyser SZ-100 (Horiba Scientific, Kyoto, Japan). The zeta potential (f) was measured using specially designed capillary zeta cells.
In vitro experiments
Encapsulation efficiency (EE) The EE of the NPs (as a percentage of the total amount of drug encapsulated) was evaluated by estimating the concentration of drug released by the NPs [19] . NPs were incubated with 1 mL of 19 PBS, pH 5.0, for 12 h on the rocker. After incubation, 30% silver nitrate (200 lL) was added and the mixture was vortexed. The resultant mixture was combined with 1 mL of high-performance liquid chromatography (HPLC)-grade methanol to extract the drug. This mixture was kept on the rocker for 2 h at room temperature followed by centrifugation at 24084 9 g for 10 min at 4°C. The collected supernatant was filtered through 0.2-lm syringe filters and the drug was quantified using HPLC at 247 nm. The mobile phase consisted of 0.1% formic acid:acetonitrile in a ratio of 25:75 (v/v), with a flow rate of 0.3 mL/min. The EE (as a percentage) was calculated using the following formula: EE = [(total amount of drug added À amount of free drug in supernatant)/total amount of drug] 9 100.
Drug release at different pH values and in simulated body fluids Three hundred micrograms of lacto-EFV-nano was incubated with 1 mL of 1X PBS at different pH values from pH 1 to 9, including simulated gastric fluid [pH 1.6 (fasted) and pH 3 (fed)] [20] and simulated intestinal fluid [pH 5.4 (fed) and pH 6.5 (fasted)] [20] . After the incubation, the drug was extracted and its concentration estimated by the silver nitrate precipitation method, as described in the previous section.
In vitro drug kinetics This experiment was performed to examine the timedependent cellular uptake of NPs. Briefly, 0.1 9 10 6 SupT1 cells were suspended in RPMI 1640 with 10% fetal bovine serum and seeded in a 12-well plate. Cells were incubated with 30 lg of soluble EFV (sol EFV) and 30 lg of lacto-EFV-nano for different times: 30 min, 1, 2, 4, 6 and 8 h. After completion of the incubation period, cells were washed in 500 lL of 19 PBS (pH 7.4) twice. The cell pellet was then re-suspended in 500 lL of lysis buffer (0.1% Triton X-100; Sigma Aldrich, Missouri, USA) followed by mild sonication for 20 S. Samples were then mixed with 1 mL of methanol and 200 lL of 30% silver nitrate, and centrifuged at 13548 9 g for 10 min. Finally, the concentration of EFV in the supernatant was determined using HPLC.
Anti-HIV-1 assay
Lacto-EFV-nano was evaluated for anti-HIV activity in vitro. Briefly, 0.1 9 10 6 SupT1 cells with 100% viability were challenged with the HIV-1 NL4-3 virus clone for 10 h. On the next day, the cells were washed thoroughly to remove any unattached viral particles and resuspended in fresh RPMI 1640 plus 10% fetal bovine serum medium. Experiments were conducted at increasing concentrations (0.1-4 nM) of soluble EFV and lacto-EFV-nano. Vehicle control (blank Lf NPs) and zidovudine (ZDV) were used over a concentration range of 0.1-15 lM. ZDV was used as a positive control. The cell supernatant at day 5 was collected and viral replication was estimated in terms of p24 using a p24 antigen capture assay (Lot No. 11111101; Advanced Bioscience Laboratories, Kensington, MD). The p24 level in the absence of drug was considered to represent 0% inhibition. The efficacy of the drug was measured in terms of percent inhibition of HIV-1 replication.
In vivo experiments
Pharmacokinetic and tissue distribution (TD) studies in rats Studies of the biodistribution of EFV-loaded Lf NPs were carried out in healthy adult albino Wistar rats weighing in the range of 160À250 g. All animals were provided with proper care, food, and water ad libitum and kept in wellventilated spacious cages throughout the study. A total of 66 rats (33 male and 33 female) were used for the PK and TD experiments. The 66 rats were divided into two groups: group 1 (control; saline-treated) contained six rats (three male and three female) and group 2 (drug-treated) contained 60 rats. These 60 rats were further divided equally into five groups, each assigned to a different time-point after administration of the formulation (30 min, 1, 2, 4 and 12 h after administration) at which they would be killed, so each group or time-point was represented by 12 rats (six male and six female). Among the 12 rats at each time-point, six rats (three male and three female) were administered soluble EFV and the remaining six (three male and three female) were administered lacto-EFVnano. All formulations were given (in a fasted state) at a dose level equivalent to 10 mg/kg body weight. At the respective time-points, the rats were killed by injecting sodium pentobarbital (50 mg/kg intraperitoneally). The tissues collected included the brain, heart, liver, lungs, kidney, spleen, oesophagus, small intestine, large intestine, stomach and bone marrow. From rats killed at the 4-h time-point, a small portion of each tissue was saved in neutral buffered formalin for histopathology. The tissues were washed with saline and homogenized using a rotor homogenizer. Then 1 mL of 30% silver nitrate per 5 mL of tissue homogenate was added to precipitate the protein.
The drug was then extracted by adding methanol and centrifuging at 12 000 rpm for 12 min, and the collected supernatant was filtered through a syringe filter and the concentration of EFV was estimated using an HPLC UV detector (Alliance Separations Module e-2695 Waters High Performance Liquid Chromatography) at 247 nm.
Tissue safety and histopathology analyses After completion of treatments for all the respective time-points, plasma was isolated from all animals. This plasma was used for the analysis of lactate dehydrogenase (LDH), the lipid profile, creatinine, aspartate transaminase (AST) and alanine aminotransferase (ALT). A safety analysis was performed using commercially available kits. Haematoxylin and eosin (H&E) tissue staining was performed and the tissues were examined microscopically for the presence of any abnormalities.
Statistical analysis
All in vitro and in vivo studies were carried out in triplicate. Data are presented as mean AE standard deviation (SD). The significance of differences between more than two groups was determined by one-way analysis of variance (ANOVA) and that of differences between two groups was determined using Student's t-test. The level of significance was set at P < 0.05.
Results
Estimation of encapsulation efficiency of nanoparticles
The EE of lacto-EFV-nano was estimated separately for five different protein concentrations, keeping the drug concentration constant. The EE estimates for different combination ratios are shown in Table S1 . The results showed that the EE was maximum for the formulation code F3 (59 AE 1.3) at a 1:3 molar ratio of EFV to Lf. Hence the formulation F3 was used throughout the study unless otherwise stated.
Nanoparticle characterization
Field emission scanning electron microscopy analysis of nanoparticles The mean diameter of blank NPs (or "lacto-nano") was 19À35 nm (Fig. 1) , while after loading of the drug, that of lacto-EFV-nano was 45À60 nm.
Size distribution, PDI and zeta potential of NPs
The DLS results ( Fig. 1) indicated the size distribution of blank and drug-loaded NPs. The hydrodynamic radii of blank and drug-loaded NPs were found to be 72 AE 3.4 nm and 103 AE 5.3 nm, respectively. The size of NPs measured by DLS was found to be larger than that obtained using FE-SEM. We infer that the larger size was caused by the water shell present around the NPs. A zeta potential of À23 AE 1.2 mV was found for lacto-EFV-nano (Fig. 1) . The PDI of lacto-EFV-nano was < 0.341.
In vitro studies pH-dependent stability of lacto-EFV-nano
The in vitro pH-dependent drug release experiment showed that maximum drug release occurred at pH 5, followed by pH 4 and 6 (Fig. 2a) . As compared to pH 5, less drug was released in simulated gastric fluids and simulated intestinal fluids, indicating that NPs were more stable and more of them remained intact during their transport through the gastrointestinal environment, thus suggesting that these intact NPs are absorbed via the oral route.
Cellular retention of lacto-EFV-nano
For the development of any new formulation, cellular drug internalization and sustained retention are essential. Drug kinetics data suggest that EFV was efficiently taken up via Lf NPs. Lacto-EFV-nano showed biphasic internalization of the drug, with a significant linear increase from 0.5 to 4.5 h, then remained constant up to 9 h, followed by a steep drop up to 12 h (Fig. 2b) . In contrast, soluble EFV uptake showed an increase up to 2 h followed by a steady decline up to 12 h. The results thus show that lacto-EFV-nano exhibited a longer cellular retention time compared with the soluble form.
Anti-HIV-1 activity of nanoparticles
The anti-HIV-1 activity of soluble EFV and lacto-EFVnano was evaluated in SupT1 cells infected with HIV-1 NL4-3 (Fig. 3a) . Lacto-EFV-nano showed dose-dependent activity in inhibition of HIV-1 replication, with a 50% inhibitory concentration (IC 50 ) of 1.1 nM, while for soluble EFV the IC 50 was 2.56 nM. Furthermore, lacto-EFVnano showed an improved dose-dependent profile. In addition, blank (without drug) Lf NPs also showed dosedependent anti-HIV-1 activity, with an IC 50 < 4 lM. The results thus suggest that lacto-EFV-nano exhibits anti-HIV-1 activity attributable to both EFV and Lf. The developed nanoformulation lacto-EFV thus works in a dual mode and hence can provide effective dual therapy against HIV-1 (Fig. 3b) .
In vivo studies
Oral pharmacokinetics study A single dose of lacto-EFV-nano or the soluble form of EFV (10 mg/kg) was administered orally to rats. Rats were killed at the time-points indicated in the "Methods" section under anaesthesia and plasma was collected. EFV was extracted using the silver nitrate method and its concentration was estimated using HPLC as described in the "Methods" section. EFV delivered through lacto-EFVnano was found to have more localize at 2 and 4 h post administration compared with the soluble form. All PK parameters were computed using KINETICA version 5.0 software (Thermo Fisher Scientific) and are shown in Table 1 . An improved PK profile in terms of a 3-4-fold increase in the area under the plasma concentrationÀtime curve (AUC) and a 6-7-fold increase in the area under the first moment curve (AUMC) was observed in rats treated with lacto-EFV-nano compared with those treated with soluble EFV. Further, rats treated with lacto-EFV-nano showed a 30% enhancement of the peak plasma concentration of the drug after oral administration (C max ) and 100% increases in the time to reach C max (T max ) and the time required for the concentration of the drug to reach half of its original value (t 1/2 ). These results suggest that the nanoformulation provides higher bioavailability coupled with an improved PK profile.
Tissue distribution
After administration of the dose of the formulation indicated in the "Methods" section, rats were killed, all the organs were homogenized and drug localization was quantified. The distribution of EFV administered in the soluble or NP form was estimated in various tissues and plotted against time (Fig. 4) . Gut tissues, such as the oesophagus, stomach and small intestine, showed higher concentrations of EFV delivered via the nanoformulation compared with the soluble form. The maximum concentration of lacto-EFV-nano was observed at 0.5 h in the oesophagus and stomach, and the next highest concentration was observed in the small intestine at 2 h, in both male and female rats. The peak plasma concentration of the nanoformulation was observed at 2 h followed by a steep decrease, whereas in the case of the soluble formulation the peak concentration was found at 1 h. The results showed that EFV delivered via the nanoformulation had a longer retention time in blood compared with the soluble formulation. In the liver, although both soluble EFV and the nanoformulation showed maximum accumulation at the 2-h time-point, the nanoformulation did not cause any toxicity, as shown in the safety data and histopathology analysis. Further, less accumulation of the nanoformulation was found in the heart, lungs, spleen, brain, large intestine, kidney and bone marrow. Results for drug localization in the kidney showed faster clearance of soluble EFV compared with its nanoformulation.
Safety and histopathology analyses of the nanoformulation The safety analysis of lacto-EFV-nano was carried out in Wistar rats. Soluble EFV treatment increased the level of LDH in both male and female rats. However, LDH levels decreased when rats were treated with lacto-EFV-nano (Fig. S4) . Detailed lipid profiles were obtained in rats treated with the soluble and NP forms of EFV. The results show that treatment with the nanoformulation produced significantly lower elevations in the level of Fig. 2 pH and time dependent drug release profile from nanoparticles (a) pH-dependent release assay measuring the release of efavirenz (EFV) from lacto-EFV-nano. Three hundred micrograms of particles was incubated in buffers of different pH, and the release of EFV was found to be maximum at pH 5, followed by pH 6 and 4. < 20% of drug less than 20% of drug was released in fasted-state simulated fluid. SIF (Fa), fasted-state simulated intestinal fluid; SIF (Fe), fed-state SIF; SGF (Fa), fasted-state simulated gastric fluid; SGF (Fe), fed-state SGF. (b) In vitro drug kinetics (cellular uptake) assay of EFV, either in soluble form (Sol-EFV) or loaded in lactoferrin nanoparticles. EFV concentrations were estimated using high-performance liquid chromatography (HPLC) at 247 nm. All data points were measured in triplicate and are denoted as mean AE standard deviation. Vehicle control (lacto-nano) and zidovudine (ZDV) (negative control) were used at concentrations of 0.2-15 lM. On the fifth day postinfection, the p24 level was measured using an enzyme-linked immunosorbent assay (ELISA). The p24 level in the absence of drugs was considered to represent 0% inhibition. Data are presented as mean and standard deviation. The level of significance is **P < 0.01 and ***P < 0.001 for the difference between lacto-EFV-nano and soluble EFV.
total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL). Kidney safety markers such as blood urea nitrogen (BUN) and creatinine were found to be significantly less elevated in nanoformulation-treated rats compared with rats treated with soluble EFV. Finally, AST and ALT levels were estimated and were found to be highly elevated in rats treated with soluble EFV, while in those treated with the nanoformulation of the drug, these levels were significantly less elevated. Tissue sections of the brain, heart, liver, spleen, kidney and gastrointestinal tract showed that there were no toxicities in these tissues when lacto-EFV-nano was administered (Fig 5) . Furthermore, lacto-EFV-nano exhibited no drug-related toxicity in any of the tissues, while there were some indications of toxicity exhibited by soluble EFV as assessed by examination of H&E staining images, which showed minor damage in liver and brain tissues (indicated by the printed arrow in Fig. 5 ).
Discussion
EFV is an NNRTI and is commonly used as the main component of HAART for HIV/AIDS treatment. EFV has a partition coefficient of 5.3 in lipophilic solvents, indicating its high lipophilicity [21] . However, as inferred from its limited aqueous solubility, it exhibits variable bioavailability. In the present study, we investigated the efficacy of lacto-EFV-nano as a therapeutic agent for treatment of HIV/AIDS. Lacto-EFV-nano was prepared using Sol-oil chemistry, which yielded particles having a mean diameter of 45À60 nm with 59% EE. In our study, we prepared NPs using different drug to protein ratios (Table S1 ). We found that the EE was maximum for the formulation ratio F3, while drug loading was maximum for the formulation ratio F1. As higher encapsulation would provide conditions for higher drug-loaded NPs per unit mass of drug, we preferred to maximize EE rather than drug loading and accordingly the formulation ratio F3 was used throughout the study. Our NP preparation procedure is simple and fast, and does not cause any chemical modification either to the protein or to the drug. Our procedure has an advantage over the other existing chitosan-based NP preparation procedure, as that procedure uses glutaraldehyde, which may affect cell viability and the chemical forms of the components [22] . A recent quantum dot-based study [23] showed that, for renal clearance, the cut-off particle size is approximately 5.5 nm, which means that any particle with a size < 5.5 nm may be excreted from the kidneys rapidly. Our NPs are usually of larger size, and will have slower renal clearance, which in turn facilitates extended blood circulation and results in a higher therapeutic index [23] . In the DLS-based analysis, the hydrodynamic sizes of blankNPs (72 AE 3.4 nm) and lacto-EFV-nano (103 AE 5.3 nm) were found to be larger than their FE-SEM sizes. DLS measures the NP size in suspension form and in this case the particle size could be affected by the interaction between the water shell and the NP surface charge, leading to an increase in the overall size. A negative surface charge of À23 AE 1.2 mV was found on the NP indicates its stability in the colloidal state. In addition, lacto-EFVnano has a PDI of < 0.341, suggesting that the particle population is homogenous in nature with a narrow particle size distribution. During lacto-EFV-nano preparation, protein and drugs were incubated together. The presence of aromatic groups such as tyrosine, phenylalanine and tryptophan in protein is responsible for the fluorescence. Fluorescence was found to increase with increased loading of the drug in the protein and was becoming saturated after 60 min (Fig. S1 ). Lacto-EFV-nano was found to be very stable even at higher temperatures, as shown by the DSC (Differential scanning calorimetry) thermogram in Fig. S2 . The thermogram of EFV-loaded Lf NPs shows the stability of EFV in the nanoformulation. Melting of EFV was observed at 138°C. Soluble EFV showed a degradation peak at 260°C, whereas this was totally absent in the nanoformulation. The position of the Pharmacokinetic parameters are as follows. AUC, area under the curve: the integral of the concentrationÀtime curve (after a single dose or in steady state); AUMC, area under the first moment curve: partial area under the moment curve between t start and t end; C max , the peak plasma concentration of a drug after oral administration; T max , time to reach C max ; t 1/2 , time required for the concentration of the drug to reach half of its original value.
endothermic peak was found to be quite similar for soluble EFV and the nanoformulation. This suggests a physical interaction between the drug and the protein. Further, the FT-IR (Fourier transform infrared spectroscopy) data show that the featured peaks related to EFV are preserved in the nanoformulation (Fig. S2c,d) . A minute variation in the position of peaks was observed in the case of lacto-EFV-nano compared with soluble EFV. This variation could be attributable to the electrostatic interaction in the nanoformulation. Lacto-nano-EFV was found to release its maximum payload at pH 5, corresponding to the endosomal pH. Exposure of lacto-EFV-nano to endosomal pH values could lead to a change in the orientation of the protein monomer, so that drug present in the cavities of the protein is released. In addition, lacto-EFVnano was found to be stable in gastric conditions, whereas the other oral formulation derived from chitosan NP disintegrates, which may limit the drug delivery potential. [24] . Further, approximately < 10% of the drug was usually released at the circulatory pH value (pH 7.4), Fig. 4 Efavirenz (EFV) tissue distribution in rats. Oral administration of soluble EFV and lacto-EFV-nano (10 mg/kg body weight) was carried out and tissues were collected at the indicated time-points followed by quantification of EFV using high-performance liquid chromatography (HPLC). "Male sol" and "Female sol" indicate the concentrations of EFV delivered via soluble EFV in male and female rats, respectively. "Male nano" and "Female nano" indicate EFV concentrations delivered via lacto-EFV-nano in male and female rats, respectively. The difference between groups was calculated using one-way analysis of variance (ANOVA); **P < 0.01 and ***P < 0.001.
thus supporting the mechanism of receptor-mediated lacto-EFV-nano entry followed by localization of lacto-EFV-nano in endosomes. These results are consistent with those of our earlier studies on oral and intravenous delivery of doxorubicin and ZDV via Apo-transferrin and Lf NPs [19, 25] . Cellular drug kinetics data showed a sustained and long-lasting release of drug from lacto-EFVnano (Fig 2b) . This property makes lacto-EFV-nano superior to other solid lipid NP which releases the drug burstly (100% of drug in < 5 min) [26] . The concentration of soluble EFV attained its maximum at 2 h followed by a steady decrease up to 12 h. In the present study, we showed that lacto-EFV-nano was at least 50% less toxic to a variety of cell lines than soluble EFV; the in vitro cell toxicity data support this conclusion (Fig. S3 ). Toxicity is an important factor to be considered, and it has been reported that soluble EFV therapy was suspended because of severe toxicity affecting the skin [27] . Our results demonstrated that lacto-EFV-nano was 1.5-fold safer than soluble EFV with respect to skin hypersensitivity. This may be seen from Fig. S3 , which shows that B16-F10 (a skin epithelial cell line) had a GI 50 (Growth Inhibition of 50%) of 57.4 and 91.2 lM for lacto-EFVnano and soluble EFV, respectively (Fig. S3) . In terms of the IC 50 , lacto-EFV-nano was found to be more effective (IC 50 = 1.1 nM) than soluble EFV (IC 50 = 2.56 nM) in blocking HIV-1 replication (Fig. 3a) . Lf blank-NPs were found to inhibit 50% of viral replication at a concentration of < 4 lM. The anti-HIV-1 activity of lacto-EFV-nano was a combined effect of the activities of EFV and Lf in the nanoformulation. An in vivo study was performed in rats of both sexes, as PK results are greatly dependent on gender. The action mechanism of the drug also depends on various parameters such as body weight, hormonal status, cardiac output and body composition [28] . Generally, women experience more adverse events than men as per the reports of the FDA [29] . The nanoformulation developed in our study resulted in an overall improvement in the PK profile when given orally to the rats. A highly significant improvement in the PK profile was observed in terms of the AUC (4-fold) and AUMC (7-fold) for the nano form of the drug compared with its soluble form in both male and female rats, and the PK profile was also better for the nanoformulation than that reported previously for another nanoformulation, which showed an improvement in the AUC of only 2.2-fold [30] . Further, a drug concentration of 200 ng/mL was found in the blood at 30 min, while negligible drug concentrations were found in the intestine. The early presence of the drug in the blood could be attributable to absorption of NPs through some alternative pathways, including the epithelial cells of the stomach [31] . A comparison of male versus female PK profiles showed that the peak values of plasma concentration (C max ) of lacto-EFV-nano were higher in female rats (535.12 ng/ml) than in male rats (440.68 ng/ml). Further, the drug exposure of lacto-EFV-nano was higher in female than in male rats, as indicated by the higher AUC tot increase for females compared with males (female > 4-fold and male > 3-fold). As a higher AUC tot is directly associated with higher systematic bioavailability of the drug, it facilitates a reduction in the dose frequency for patients. In addition, other PK parameters such as AUMC tot , T max and t 1/2 were also found to be significantly improved in nanoformulation-treated rats compared with rats treated with soluble EFV. Increases of 100% in T max and t 1/2 were found in NP-treated rats (female and male) relative to soluble EFV-treated rats, suggesting a slow and sustained release of the drug via lacto-EFV-nano. In spite of higher accumulation of lacto-EFV-nano than soluble EFV in the liver, less liver toxicity was observed, as shown in histopathology images. Earlier reports demonstrated that EFV treatment leads to liver damage and neurocognitive reactions, such as anxiety [32] . The low hepatotoxicity observed in the case of lacto-EFV-nano could be attributable to protection of EFV by the Lf protein nanoshell, so that further release of the drug into the liver is not possible, thus reducing the possibility of drug-related toxicity.
Results of the comparison of the biochemical safety profiles of nano and soluble forms of EFV showed a significant difference in plasma AST and ALT between the nano and soluble forms in both male and female rats.
Creatinine and BUN showed significant decrease (P < 0.001), suggesting low kidney toxicity, when the nanoformulation was used compared with soluble EFV (Fig. S4) . Further, treatment with lacto-EFV-nano did not show any significant differences in lipid profile in male and female rats compare with soluble efavirenz. Any novel drug formulation cannot be used successfully unless and until it fulfils requirements for stability under different physical and environmental conditions. Lacto-EFV-nano developed in the present study was found to be highly stable and effective and had an improved PK profile, compared with the soluble form of EFV, when administered orally.
Conclusions
The present study shows the applicability of a proteinbased formulation in increasing the absorption of lipophilic drugs. In this study, stable EFV-loaded Lf NPs were formulated using appropriate proportions of protein and drug. This formulation showed optimally stable physicochemical parameters with higher bioavailability in terms of the values of C max, t 1/2 and AUC. Further, it was shown that the nanoformulation had enhanced anti-HIV-1 activity and reduced EFV toxicity compared with soluble EFV. 
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